---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-037586"
form_type: "8-K"
ticker: "VRDN"
cik: "0001590750"
company_name: "Viridian Therapeutics, Inc.\\DE"
filed_at: "2025-02-27T23:59:59+00:00"
generated_at: "2026-05-26T01:52:03.304135+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Viridian reports positive phase 3 data for veligrotug in TED; cash $717.6M

## Summary
- Veligrotug met all primary and secondary endpoints in THRIVE and THRIVE-2 for active and chronic TED.
- BLA submission on track for 2H 2025; MAA submission expected 1H 2026.
- Cash, equivalents, and investments $717.6M as of Dec 31, 2024, funding operations into 2H 2027.
- Net loss $269.9M for 2024 vs $237.7M in 2023; R&D expenses rose to $238.3M.
- Appointed Radhika Tripuraneni as CMO, succeeding Thomas Ciulla who transitions to consultant.

## SEC filing metadata
- accession: 0001193125-25-037586
- form_type: 8-K
- ticker: VRDN
- cik: 0001590750
- company_name: Viridian Therapeutics, Inc.\DE
- filed_at: 2025-02-27T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1590750/000119312525037586/0001193125-25-037586-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1590750/000119312525037586/d865236d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-037586
- JSON: https://secwatch.observer/filing/0001193125-25-037586.json
- Plain text: https://secwatch.observer/filing/0001193125-25-037586.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.